Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | FPR3 | P25089 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25632160 | 0.83 | GLS (0.45) | GLSCYP3A4CYP2C19SMN1; SMN2HPGD | |
| SCHEMBL29306659 | 0.82 | SPHK1 (0.46) | GLSSMN1; SMN2HPGDLMNANPSR1 | |
| SCHEMBL25632161 | 0.76 | DRD2 (0.42) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA | |
| SCHEMBL24654080 | 0.76 | CYP3A4 (0.41) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA | |
| SCHEMBL29306394 | 0.76 | CYP3A4 (0.43) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA | |
| SCHEMBL24654083 | 0.75 | DRD2 (0.44) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA | |
| SCHEMBL24654166 | 0.75 | CYP3A4 (0.37) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA | |
| SCHEMBL26717052 | 0.71 | CYP3A4 (0.38) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA | |
| SCHEMBL24654081 | 0.70 | CYP2C19 (0.37) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA | |
| SCHEMBL24654082 | 0.70 | CYP3A4 (0.41) | CYP3A4CYP2C19SMN1; SMN2HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-11 | — | — | US | disclosed |
| WO-2022204288-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226026-A1 | BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PLTP, LNPK, PLIN3 | GLS 934/4885CYP3A4 4877/4885CYP2C19 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.